GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Gilead Sciences (GILD) shares fell 2.2% after CVS Health decided not to cover its newly FDA-approved HIV prevention drug, Yeztugo, under its commercial plans, citing clinical, financial, and regulatory factors for the drug that carries a U.S. list price over $28,000 annually. This decision is expected to impact Yeztugo's market uptake, despite it being the first and only twice-yearly PrEP option. Concurrently, Gilead's Kite subsidiary announced the acquisition of Interius BioTherapeutics for $350 million, a strategic move into in vivo CAR therapeutics that is projected to dilute GILD's EPS by $0.23-$0.25.

Analysis

Gilead Sciences (GILD) experienced a notable setback with its shares falling 2.2% following the decision by pharmacy benefit manager CVS Health not to include the newly approved HIV prevention drug, Yeztugo, in its commercial formularies. This decision, attributed to clinical, financial, and regulatory factors, directly challenges Yeztugo's market uptake, particularly given its high list price of over $28,000 annually. The development casts doubt on Gilead's stated goal of achieving 75% insurer coverage by year-end. While this presents a significant near-term headwind for a key product launch, Gilead is simultaneously pursuing a long-term strategic initiative. Its subsidiary, Kite, announced a $350 million acquisition of Interius BioTherapeutics, a move that provides entry into the next-generation in vivo CAR therapeutics space. This acquisition, however, comes with an immediate financial cost, as it is expected to be dilutive to Gilead's bottom line by approximately $0.23 to $0.25 per share. Despite the day's negative news, the stock's year-to-date performance remains strong at a 25.7% gain, substantially outpacing the industry's 4% growth.

Key Decisions for Investors

• Investors should closely monitor near-term developments regarding Yeztugo's formulary negotiations with other major insurers, as broad market access is critical to validating the drug's revenue potential and overcoming the CVS setback.
• The acquisition of Interius BioTherapeutics represents a long-term investment in a potentially disruptive cell therapy platform; therefore, one must weigh the immediate EPS dilution against the strategic value and future growth optionality this adds to Kite's portfolio.
• Given that GILD stock has significantly outperformed its industry year-to-date, this 2.2% pullback could be viewed as either a buying opportunity for those confident in the long-term pipeline or a signal to exercise caution as near-term growth catalysts face new uncertainty.